Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies DOI Open Access
Adam Khorasanchi, Karan Jatwani, Lingbin Meng

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(24), P. 4127 - 4127

Published: Dec. 10, 2024

Genitourinary (GU) malignancies are common and associated with significant morbidity mortality. In patients localized GU cancers, surgical resection or definitive radiation remain the mainstays of treatment. Despite treatment, many high-risk disease experience recurrence. There is growing interest in using neoadjuvant immunotherapy to improve outcomes. This narrative review summarizes current evidence for cancers including renal cell carcinoma, urothelial prostate cancer, penile squamous testicular germ tumors. We also discuss ongoing clinical trials candidate biomarkers optimize patient selection treatment

Language: Английский

Neoadjuvant Chemoimmunotherapy for Resectable Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-analysis DOI
Lei‐Ming Cao, Yi-Fu Yu, Zi‐Zhan Li

et al.

Annals of Surgical Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: March 18, 2025

Language: Английский

Citations

1

Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment DOI
Lei‐Ming Cao, Nian‐Nian Zhong, Yang Chen

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 598, P. 217095 - 217095

Published: July 2, 2024

Language: Английский

Citations

7

The Evolving Landscape of Neoadjuvant Immunotherapy in Gastroesophageal Cancer DOI Open Access
Colum Dennehy,

Alisha F. Khan,

Ali H. Zaidi

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(2), P. 286 - 286

Published: Jan. 9, 2024

Despite advances in treatment strategies and surgical approaches recent years, improving survival outcomes esophagogastric cancer (EGC) patients treated with curative intent remains a significant area of unmet need. The emergence adjuvant immunotherapy as the standard care for resected EGC demonstrates impact recurrence-free survival. Neoadjuvant perioperative immunotherapies represent another promising approach potential advantages over therapy. results early neoadjuvant studies, there are several challenges future research needs. optimal timing, duration number doses relation to surgery combination still unclear. In addition, rigorous correlative studies need be performed identify biomarkers patient selection response prediction maximize benefits immunotherapy. this review, we provide concise summary current resectable discuss rationale use immune checkpoint inhibitors setting pre-clinical clinical data these novel therapies. Finally, will examine role direction paradigm perceived opportunities that lay ahead.

Language: Английский

Citations

4

Budget impact analysis of neoadjuvant nivolumab for non-small cell lung cancer in the Chilean public healthcare system: An exploratory economic assessment DOI Creative Commons
Daniela Paredes-Fernández, Rony Lenz-Alcayaga,

Francisco Orlandi-Jorquera

et al.

Clinical & Translational Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: March 2, 2025

Abstract Purpose Effective and sustainable treatments to improve patient outcomes are urgently needed for non-small cell lung carcinoma (NSCLC). Neoadjuvant therapies, particularly nivolumab, have shown superior in event-free survival pathological response, yet financial coverage is scarce. We aim provide an exploratory economic analysis assess the implications of its incorporation into routine clinical practice. Methods conducted a six-step BIA (budget impact analysis) based on decision tree model pathways, probabilities, resource utilization from national payer perspective at (EFS) horizon. estimated direct cost drugs all healthcare-related services two scenarios: baseline scenario [neoadjuvant chemotherapy (CT)] alternative nivolumab combined with (N + CT)]. Results The funnel-down technique determined 359 eligible patients nationwide per year. total treatment amounts CLP $ 7315 million Chilean pesos (€ 8,063,219) cohort, three top drivers: 1L after recurrence (51.98%), resection (29.33%) 2L (5.85%). amounted 6853 7,553,572), highest relative expenditure attributed N CT scheme (61.76%), (31.31%), follow-up (2.73%). Adjuvant costs decrease 1.03%, as does (51.98% versus 0.34%) (5.85% 0.18%). Early intervention NSCLC reduces budgetary by 6.3% (savings − 462 509,647) treated cohort). Conclusions optimizes healthcare providing access therapies that rates while reducing need costly advanced stages. This approach represents dominant strategy.

Language: Английский

Citations

0

Updated cost-effectiveness analysis of tislelizumab in combination with chemotherapy for the first-line treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma DOI Creative Commons
Lei Xu, Yunchun Long, Yao Lü

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Dec. 16, 2024

The RATIONALE-305 trial demonstrated that tislelizumab in combination with chemotherapy regimens was more beneficial than alone the treatment of patients advanced gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJC). This study aimed to evaluate cost-effectiveness GC/GEJC from perspective Chinese health service system.

Language: Английский

Citations

1

The efficacy and safety of neoadjuvant immunochemotherapy in resectable stage I-III non-small cell lung cancer: a systematic review and network meta-analysis DOI
Bo Li,

Yujia Gu,

Weixing Zhao

et al.

Clinical & Translational Oncology, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 9, 2024

Language: Английский

Citations

0

Role of Neoadjuvant Immunotherapy in Genitourinary Malignancies DOI Open Access
Adam Khorasanchi, Karan Jatwani, Lingbin Meng

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(24), P. 4127 - 4127

Published: Dec. 10, 2024

Genitourinary (GU) malignancies are common and associated with significant morbidity mortality. In patients localized GU cancers, surgical resection or definitive radiation remain the mainstays of treatment. Despite treatment, many high-risk disease experience recurrence. There is growing interest in using neoadjuvant immunotherapy to improve outcomes. This narrative review summarizes current evidence for cancers including renal cell carcinoma, urothelial prostate cancer, penile squamous testicular germ tumors. We also discuss ongoing clinical trials candidate biomarkers optimize patient selection treatment

Language: Английский

Citations

0